ASCO 2023 – Behind Astellas comes Elevation
Elevation’s anti-Claudin18.2 antibody-drug conjugate generates some justified optimism, but Zai Lab’s zolbetuximab challenger is out of luck.
ASCO 2023 – ovarian cancer could provide a role for immuno-oncology at last
Excluding BRCA-positive patients could be the key to Imfinzi’s apparent success in ovarian cancer, Astra’s Duo-O suggests.
ASCO 2023 – Bristol’s Commands data look good for Geron
The limited activity of Reblozyl in myelodysplastic syndromes patients without ringed sideroblasts could help Geron.
ASCO 2023 – in Lag3 Regeneron could beat Bristol Myers Squibb
Regeneron’s fianlimab could be biopharma’s most potent Lag3 project, and has shown activity in a new melanoma setting
Vulputate cursus a sit amet mauris
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Morbi ac neque at mi elementum gravida et vitae elit. Etiam ullamcorper auctor orci, id luctus felis laoreet a. Nam nec nulla sit amet tellus pretium rhoncus. Integer interdum, nibh sed posuere aliquet, enim ante lacinia augue, ut ultricies augue erat vel lorem. Vestibulum bibendum dolor sit amet tincidunt lacinia. Nunc sapien libero, condimentum et turpis eget, eleifend hendrerit augue. Duis molestie volutpat feugiat.
Cras consectetur tincidunt neque
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Morbi ac neque at mi elementum gravida et vitae elit. Etiam ullamcorper auctor orci, id luctus felis laoreet a. Nam nec nulla sit amet tellus pretium rhoncus. Integer interdum, nibh sed posuere aliquet, enim ante lacinia augue, ut ultricies augue erat vel lorem. Vestibulum bibendum dolor sit amet tincidunt lacinia. Nunc sapien libero, condimentum et turpis eget, eleifend hendrerit augue. Duis molestie volutpat feugiat.
